{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:03:08Z","timestamp":1789578188129,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82460482"],"award-info":[{"award-number":["82460482"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20202BAB216033"],"award-info":[{"award-number":["20202BAB216033"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Endosc"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00464-026-13090-z","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:35:15Z","timestamp":1783611315000},"page":"7736-7745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factors and the role of pelvic lymph node dissection in oligometastatic prostate cancer: a multicenter exploratory study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5136-2958","authenticated-orcid":false,"given":"Jieping","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weipeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"3","key":"13090_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA: Cancer J Clin"},{"issue":"16","key":"13090_CR2","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","volume":"333","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB (2025) Prostate cancer: a review. JAMA 333(16):1433\u20131446. https:\/\/doi.org\/10.1001\/jama.2025.0228","journal-title":"JAMA"},{"key":"13090_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010147","author":"P Alerasool","year":"2025","unstructured":"Alerasool P, Zhou S, Miller E, Anker J, Tsao B, Kyprianou N et al (2025) A personalized approach for oligometastatic prostate cancer: current understanding and future directions. Cancers. https:\/\/doi.org\/10.3390\/cancers17010147","journal-title":"Cancers"},{"issue":"4","key":"13090_CR4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.euo.2023.09.006","volume":"7","author":"P Rajwa","year":"2024","unstructured":"Rajwa P, Robesti D, Chaloupka M, Zattoni F, Giesen A, Huebner NA et al (2024) Outcomes of cytoreductive radical prostatectomy for oligometastatic prostate cancer on prostate-specific membrane antigen positron emission tomography: results of a multicenter european study. Eur Urol Oncol 7(4):721\u2013734. https:\/\/doi.org\/10.1016\/j.euo.2023.09.006","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"13090_CR5","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/mou.0000000000001180","volume":"34","author":"D Robesti","year":"2024","unstructured":"Robesti D, Gallina A, Montorsi F, Briganti A, Fossati N (2024) Role of cytoreductive radical prostatectomy in men with oligometastatic prostate cancer on molecular imaging. Curr Opin Urol 34(4):294\u2013299. https:\/\/doi.org\/10.1097\/mou.0000000000001180","journal-title":"Curr Opin Urol"},{"key":"13090_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030507","author":"R Oka","year":"2024","unstructured":"Oka R, Utsumi T, Noro T, Suzuki Y, Iijima S, Sugizaki Y et al (2024) Progress in oligometastatic prostate cancer: emerging imaging Innovations and therapeutic approaches. Cancers. https:\/\/doi.org\/10.3390\/cancers16030507","journal-title":"Cancers"},{"key":"13090_CR7","doi-asserted-by":"publisher","first-page":"1368926","DOI":"10.3389\/fonc.2024.1368926","volume":"14","author":"WS Ham","year":"2024","unstructured":"Ham WS, Park JS, Jang WS, Kim J (2024) Radical prostatectomy versus radiotherapy as local therapy for primary tumors in patients with oligometastatic prostate cancer. Front Oncol 14:1368926. https:\/\/doi.org\/10.3389\/fonc.2024.1368926","journal-title":"Front Oncol"},{"key":"13090_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.09.4144","author":"M Graefen","year":"2025","unstructured":"Graefen M, Falkenbach F, Maurer T, Bud\u00e4us L, Tilki D, Karakiewicz PI et al (2025) Best systemic therapy with or without radical prostatectomy in the management of men with oligometastatic prostate cancer: the rampp randomised controlled Trial. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4144","journal-title":"Eur Urol"},{"issue":"17","key":"13090_CR9","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.3390\/cancers17172757","volume":"17","author":"K Rajan","year":"2025","unstructured":"Rajan K, Parmar K, Rajamoorthy SI, Geraghty R, Whyte E, Rai BP (2025) Role of radical prostatectomy in oligo-metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Cancers 17(17):2757. https:\/\/doi.org\/10.3390\/cancers17172757","journal-title":"Cancers"},{"key":"13090_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s12262-024-04153-3","author":"JP Hu","year":"2024","unstructured":"Hu JP, Huang S, Hong YY, Liu WP (2024) The Prognostic role of lymph node dissection for high-risk localized prostate cancer patients: a population-based, retrospective cohort study. Indian J Surg. https:\/\/doi.org\/10.1007\/s12262-024-04153-3","journal-title":"Indian J Surg"},{"key":"13090_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.953069","volume":"12","author":"J Hu","year":"2022","unstructured":"Hu J, Yu Y, Liu W, Zhong J, Zhou X, Xi H (2022) The survival benefit of different lymph node yields in radical prostatectomy for pN1M0 prostate cancer patients: Implications from a population-based study. Front Oncol 12:953069. https:\/\/doi.org\/10.3389\/fonc.2022.953069","journal-title":"Front Oncol"},{"key":"13090_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-025-04694-w","author":"L Li","year":"2025","unstructured":"Li L, Hu Z, Li C, Zhang L, Hu J (2025) Absence of independent prognostic impact of node status in M1 prostate cancer: implications from a SEER-based study. Int Urol Nephrol. https:\/\/doi.org\/10.1007\/s11255-025-04694-w","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"13090_CR13","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.21037\/tau-20-729","volume":"9","author":"DC Cheung","year":"2020","unstructured":"Cheung DC, Fleshner N, Sengupta S, Woon D (2020) A narrative review of pelvic lymph node dissection in prostate cancer. Transl Androl Urol 9(6):3049\u20133055. https:\/\/doi.org\/10.21037\/tau-20-729","journal-title":"Transl Androl Urol"},{"issue":"6","key":"13090_CR14","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1078-0432.Ccr-24-3027","volume":"31","author":"JR Andrews","year":"2025","unstructured":"Andrews JR, Kim Y, Horjeti E, Arafa A, Gunn H, De Bruycker A et al (2025) PSMA+ extracellular vesicles are a biomarker for SABR in oligorecurrent prostate cancer: analysis from the STOMP-like and ORIOLE trial cohorts. Clin Cancer Res: An Official J Am Assoc Cancer Res 31(6):1142\u20131149. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-3027","journal-title":"Clin Cancer Res: An Official J Am Assoc Cancer Res"},{"key":"13090_CR15","doi-asserted-by":"publisher","first-page":"8867","DOI":"10.2147\/cmar.S270882","volume":"12","author":"P Xue","year":"2020","unstructured":"Xue P, Wu Z, Wang K, Gao G, Zhuang M, Yan M (2020) Oncological outcome of combining cytoreductive prostatectomy and metastasis-directed radiotherapy in patients with prostate cancer and bone oligometastases: a retrospective cohort study. Cancer Manage Res 12:8867\u20138873. https:\/\/doi.org\/10.2147\/cmar.S270882","journal-title":"Cancer Manage Res"},{"issue":"12","key":"13090_CR16","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/jco.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K et al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clinic Oncol 34(12):1402\u20131418. https:\/\/doi.org\/10.1200\/jco.2015.64.2702","journal-title":"J Clinic Oncol"},{"key":"13090_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/biom15050625","author":"WA Kwon","year":"2025","unstructured":"Kwon WA, Joung JY (2025) Precision targeting in metastatic prostate cancer: molecular insights to therapeutic frontiers. Biomolecules. https:\/\/doi.org\/10.3390\/biom15050625","journal-title":"Biomolecules"},{"issue":"2","key":"13090_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.09.009","volume":"6","author":"X Bian","year":"2025","unstructured":"Bian X, Gu W, Zhang X, Xie L, Wang S, Shi B et al (2025) Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial. Med (New York, NY) 6(2):100520. https:\/\/doi.org\/10.1016\/j.medj.2024.09.009","journal-title":"Med (New York, NY)"},{"issue":"1","key":"13090_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s00345-024-05414-2","volume":"43","author":"J Troidl","year":"2025","unstructured":"Troidl J, Fehr A, Jandrig B, K\u00f6llermann J, Lux A, Baumunk D et al (2025) More micrometastases, more recurrence? The role of qPCR of PSA mRNA in lymph nodes during prostatectomy. World J Urol 43(1):62. https:\/\/doi.org\/10.1007\/s00345-024-05414-2","journal-title":"World J Urol"},{"issue":"7","key":"13090_CR20","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.7150\/ijbs.129521","volume":"22","author":"Y Wang","year":"2026","unstructured":"Wang Y, Wu N, Li J, Cao Q, Ye J, Zhang S (2026) The quartet of core oncogenic drivers in neuroendocrine prostate cancer: multi-omics dataset integration to forge a translational link between biology and precision therapy. Int J Biol Sci 22(7):3564\u20133579. https:\/\/doi.org\/10.7150\/ijbs.129521","journal-title":"Int J Biol Sci"},{"key":"13090_CR21","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.34133\/research.1128","volume":"2026","author":"J Ye","year":"2026","unstructured":"Ye J, Xie Y, Wang J, Wu R, Li D, Yoo KH et al (2026) Intratumoral androgens and genetic variants driving therapy resistance in prostate cancer. Res (Wash, DC) 2026:1128. https:\/\/doi.org\/10.34133\/research.1128","journal-title":"Res (Wash, DC)"},{"issue":"3","key":"13090_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10147-022-02288-5","volume":"28","author":"T Oka","year":"2023","unstructured":"Oka T, Hatano K, Okuda Y, Yamamoto A, Uemura T, Yamamichi G et al (2023) The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer. Int J Clin Oncol 28(3):427\u2013435. https:\/\/doi.org\/10.1007\/s10147-022-02288-5","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"13090_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/bco2.70074","volume":"6","author":"T Ogata","year":"2025","unstructured":"Ogata T, Aizawa R, Abe H, Goto T, Nakamura K, Kita Y et al (2025) Development of a novel risk model to predict CRPC progression following IMRT: Implications for tailoring treatment intensity. BJUI compass 6(9):e70074. https:\/\/doi.org\/10.1002\/bco2.70074","journal-title":"BJUI compass"},{"key":"13090_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/22143602261438534","author":"A Aartsma-Rus","year":"2026","unstructured":"Aartsma-Rus A, Robertson L, Alfano LN, Mayhew A, Gordish-Dressman H, Kelly M et al (2026) TREAT-NMD advisory committee for therapeutics: preclinical and clinical learnings from 15 years of TACT. J Neuromuscul Dis. https:\/\/doi.org\/10.1177\/22143602261438534","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"13090_CR25","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1097\/js9.0000000000000997","volume":"110","author":"G Ding","year":"2024","unstructured":"Ding G, Tang G, Wang T, Zou Q, Cui Y, Wu J (2024) A comparative analysis of perioperative complications and biochemical recurrence between standard and extended pelvic lymph node dissection in prostate cancer patients undergoing radical prostatectomy: a systematic review and meta-analysis. Int J Surg (Lond, Engl) 110(3):1735\u20131743. https:\/\/doi.org\/10.1097\/js9.0000000000000997","journal-title":"Int J Surg (Lond, Engl)"},{"key":"13090_CR26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269189","author":"W Tang","year":"2025","unstructured":"Tang W, Qi L, Chen M, Zhang Y, Tang Y, Hu S et al (2025) Additive value of [(68)Ga]Ga-RM26 PET\/CT to [(68)Ga]Ga-PSMA-617 PET\/CT in detecting pelvic lymph node metastasis in prostate cancer: a prospective, single-center, phase II study. J Nucl Med. https:\/\/doi.org\/10.2967\/jnumed.124.269189","journal-title":"J Nucl Med"},{"key":"13090_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-023-03931-4","author":"J Hu","year":"2024","unstructured":"Hu J, Yang X, Xiong Z, Xie X, Hong Y, Liu W (2024) Analysis of biopsy pathology and risk factors of lymph node metastasis in prostate cancer. Int Urol Nephrol. https:\/\/doi.org\/10.1007\/s11255-023-03931-4","journal-title":"Int Urol Nephrol"},{"issue":"16","key":"13090_CR28","doi-asserted-by":"publisher","first-page":"16697","DOI":"10.1002\/cam4.6292","volume":"12","author":"T Zhai","year":"2023","unstructured":"Zhai T, Ma J, Liu Y, Li H, Peng Y, Guo W et al (2023) The role of cytoreductive radical prostatectomy and lymph node dissection in bone-metastatic prostate cancer: a population-based study. Cancer Med 12(16):16697\u201316706. https:\/\/doi.org\/10.1002\/cam4.6292","journal-title":"Cancer Med"},{"key":"13090_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-024-00912-9","author":"R Gupta","year":"2024","unstructured":"Gupta R, Das CK, Nair SS, Pedraza-Bermeo AM, Zahalka AH, Kyprianou N et al (2024) From foes to friends: rethinking the role of lymph nodes in prostate cancer. Nat Rev Urol. https:\/\/doi.org\/10.1038\/s41585-024-00912-9","journal-title":"Nat Rev Urol"},{"key":"13090_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.euros.2025.02.002","volume":"74","author":"YJ Chou","year":"2025","unstructured":"Chou YJ, Chang CL, Tsai YC (2025) Diagnostic accuracy of indocyanine green-stained sentinel lymph nodes in prostate cancer patients: a systematic review and meta-analysis. Eur Urol Open Sci 74:34\u201343. https:\/\/doi.org\/10.1016\/j.euros.2025.02.002","journal-title":"Eur Urol Open Sci"},{"key":"13090_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00752-5","author":"A Saouli","year":"2023","unstructured":"Saouli A, Touzani A, Martini A, Beauval JB, Dergamoun H, Ziouziou I et al (2023) Is there a role for radical prostatectomy in the management of oligometastatic prostate cancer? A systematic review. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-023-00752-5","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"13090_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-02521-7","author":"K Zhou","year":"2025","unstructured":"Zhou K, Lu H, Wei F, Wang J, Song Z, Mao L (2025) Pathologic response as an early endpoint for survival following neoadjuvant androgen deprivation therapy plus abiraterone acetate for metastatic prostate cancer. Eur J Med Res. https:\/\/doi.org\/10.1186\/s40001-025-02521-7","journal-title":"Eur J Med Res"},{"issue":"5","key":"13090_CR33","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.eururo.2020.11.040","volume":"79","author":"JFP Lestingi","year":"2021","unstructured":"Lestingi JFP, Guglielmetti GB, Trinh QD, Coelho RF, Pontes J Jr, Bastos DA et al (2021) Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial. Eur Urol 79(5):595\u2013604. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.040","journal-title":"Eur Urol"},{"issue":"7","key":"13090_CR34","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s11255-023-03622-0","volume":"55","author":"N Maskey","year":"2023","unstructured":"Maskey N, Mao S, Yang G, Guo Y, Kadier A, Yuan J et al (2023) Perioperative change of circulating tumor cells in cytoreductive radical prostatectomy for oligometastatic hormone-sensitive prostate cancer: the preliminary safety evidence from long-term oncologic outcomes. Int Urol Nephrol 55(7):1709\u20131717. https:\/\/doi.org\/10.1007\/s11255-023-03622-0","journal-title":"Int Urol Nephrol"},{"key":"13090_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.111237","volume":"214","author":"J von der Gr\u00fcn","year":"2026","unstructured":"von der Gr\u00fcn J, Regnery S, H\u00f6rner-Rieber J, Hoegen-Sa\u00dfmannshausen P, Andratschke N, Tanadini-Lang S et al (2026) Multicenter analysis of MRI-guided, stereotactic body radiotherapy as ablative treatment for lymph nodal metastases of the abdomen and pelvis. Radiother Oncol: J Eur Soc Ther Radiol Oncol 214:111237. https:\/\/doi.org\/10.1016\/j.radonc.2025.111237","journal-title":"Radiother Oncol: J Eur Soc Ther Radiol Oncol"}],"container-title":["Surgical Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-026-13090-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00464-026-13090-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-026-13090-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:17:33Z","timestamp":1789575453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00464-026-13090-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["13090"],"URL":"https:\/\/doi.org\/10.1007\/s00464-026-13090-z","relation":{},"ISSN":["0930-2794","1432-2218"],"issn-type":[{"value":"0930-2794","type":"print"},{"value":"1432-2218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jieping Hu, Yuyang Yuan, Xinchang Zou, Xiaoqiang Liu, Weipeng Liu, Yujie Dong, Baojun Wang, and Bin Fu have no conflicts of interest or financial ties to disclose.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with the guidelines for human studies and was conducted in accordance with the World Medical Association Declaration of Helsinki. The study protocol was approved by the First Affiliated Hospital of Nanchang University in China.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}